GILZ转录变异体1高表达与脓毒症30天死亡率增加相关,高表达比值可能提示氢化可的松禁忌
本研究纳入符合Sepsis-3标准的脓毒症患者121例,检测全血GILZ转录变异体mRNA表达,并在单核细胞U937细胞系(n=3)中观察氢化可的松和脂多糖对GILZ TV1的影响。结果显示,脓毒症发病第1天内GILZ TV1升高与30天死亡率增加相关(2.2倍,95%CI 1.2-4.3),至第8天升至8.5倍(95%CI 2.0-36.4)。细胞培养中糖皮质激素增强GILZ TV1表达,而LPS等炎症刺激不影响;脓毒症患者中GILZ TV1随病程及氢化可的松治疗升高。TV1相对所有GILZ转录变异体的高表达比值与接受氢化可的松治疗者死亡率高2.3倍相关,提示该比值可用于识别氢化可的松可能禁忌的患者亚组。
要点
- 脓毒症发病第1天内GILZ TV1升高与30天死亡率增加相关(2.2倍,95%CI 1.2-4.3),第8天升至8.5倍(95%CI 2.0-36.4)。
- 细胞培养中糖皮质激素增强GILZ TV1表达,LPS等炎症刺激不影响GILZ TV1表达。
- 脓毒症患者中GILZ TV1表达随病程及氢化可的松治疗而升高。
- TV1相对所有GILZ转录变异体的高表达比值与接受氢化可的松治疗者死亡率高2.3倍相关。
- 作者认为,TV1相对所有GILZ转录变异体的高表达比值可用于识别氢化可的松可能禁忌的患者亚组。
适用人群与场景
- 符合Sepsis-3标准的脓毒症患者(n=121),全血样本检测GILZ转录变异体mRNA表达。
- 单核细胞U937细胞系(n=3),用于观察氢化可的松和脂多糖对GILZ TV1表达的影响。
诊断标准与关键阈值
- 脓毒症诊断采用Sepsis-3标准。
- GILZ TV1高表达定义为与30天死亡率增加相关(第1天2.2倍,95%CI 1.2-4.3;第8天8.5倍,95%CI 2.0-36.4)。
- TV1相对所有GILZ转录变异体的高表达比值与接受氢化可的松治疗者死亡率高2.3倍相关。
研究设计与关键结果
- 研究类型:观察性研究(脓毒症患者队列)及细胞实验(U937细胞系)。
- 样本量:脓毒症患者n=121,U937细胞系n=3。
- 主要终点:脓毒症发病第1天内GILZ TV1升高与30天死亡率增加相关(2.2倍,95%CI 1.2-4.3),第8天升至8.5倍(95%CI 2.0-36.4)。
- 细胞实验:糖皮质激素增强GILZ TV1表达,LPS等炎症刺激不影响GILZ TV1表达。
- 患者数据:脓毒症患者中GILZ TV1表达随病程及氢化可的松治疗而升高。
- 亚组分析:TV1相对所有GILZ转录变异体的高表达比值与接受氢化可的松治疗者死亡率高2.3倍相关。
证据类型、等级与局限
- 证据类型:观察性研究(脓毒症患者队列)及细胞实验(U937细胞系)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,GILZ TV1相对所有GILZ转录变异体的高表达比值是识别氢化可的松可能禁忌患者亚组的参数。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Sepsis presents a challenge due to its complex immune responses, where balance between inflammation and anti-inflammation is critical for survival. Glucocorticoid-induced leucine zipper (GILZ) is key protein in achieving this balance, suppressing inflammation and mediating glucocorticoid response. This study aims to investigate GILZ transcript variants in sepsis patients and explore their potential for patient stratification and optimizing glucocorticoid therapy.
METHODS: Sepsis patients meeting the criteria outlined in Sepsis-3 were enrolled, and RNA was isolated from whole blood samples. Quantitative mRNA expression of GILZ transcript variants in both sepsis patient samples (n = 121) and the monocytic U937 cell line (n = 3), treated with hydrocortisone and lipopolysaccharides, was assessed using quantitative PCR (qPCR).
RESULTS: Elevated expression of GILZ transcript variant 1 (GILZ TV 1) serves as a marker for heightened 30-day mortality in septic patients. Increased levels of GILZ TV 1 within the initial day of sepsis onset are associated with a 2.2-[95% CI 1.2-4.3] fold rise in mortality, escalating to an 8.5-[95% CI 2.0-36.4] fold increase by day eight. GILZ TV1 expression is enhanced by glucocorticoids in cell culture but remains unaffected by inflammatory stimuli such as LPS. In septic patients, GILZ TV 1 expression increases over the course of sepsis and in response to hydrocortisone treatment. Furthermore, a high expression ratio of transcript variant 1 relative to all GILZ mRNA TVs correlates with a 2.3-fold higher mortality rate in patients receiving hydrocortisone treatment.
CONCLUSION: High expression of GILZ TV 1 is associated with a higher 30-day sepsis mortality rate. Moreover, a high expression ratio of GILZ TV 1 relative to all GILZ transcript variants is a parameter for identifying patient subgroups in which hydrocortisone may be contraindicated.
参考来源
- Rusev S, Thon P, Dyck B, et al. High expression of L-GILZ transcript variant 1 (GILZ TV 1) is associated with increased 30-day sepsis mortality, and a high expression ratio possibly contraindicates hydrocortisone administration. Crit Care. 2024. PMID: 39135180. doi:10.1186/s13054-024-05056-1
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。